Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.

Stancu AL, Smith MR, Almasan A.

Discoveries (Craiova). 2014 Jan-Mar;2(1). pii: e14.

2.

Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.

Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES, Wetzler M.

Blood Rev. 2015 Jul;29(4):243-9. doi: 10.1016/j.blre.2015.01.001. Review.

3.

Clinically relevant pharmacogenomic testing in pediatric practice.

Korbel L, George M, Kitzmiller J.

Clin Pediatr (Phila). 2014 Aug;53(9):831-8. doi: 10.1177/0009922814533186.

4.

Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia.

Stocco G, Franca R, Verzegnassi F, Londero M, Rabusin M, Decorti G.

Front Genet. 2013 Jan 7;3:309. doi: 10.3389/fgene.2012.00309.

5.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

Pui CH, Mullighan CG, Evans WE, Relling MV.

Blood. 2012 Aug 9;120(6):1165-74. doi: 10.1182/blood-2012-05-378943. Review.

6.

Using germline genomics to individualize pediatric cancer treatments.

Pinto N, Cohn SL, Dolan ME.

Clin Cancer Res. 2012 May 15;18(10):2791-800. doi: 10.1158/1078-0432.CCR-11-1938. Review.

7.

Pharmacogenetics, cost of genotyping, and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia.

Stocco G, Crews KR.

Pediatr Blood Cancer. 2011 Dec 15;57(7):1247. doi: 10.1002/pbc.23249. No abstract available.

8.

Cancer pharmacogenomics.

Paugh SW, Stocco G, McCorkle JR, Diouf B, Crews KR, Evans WE.

Clin Pharmacol Ther. 2011 Sep;90(3):461-6. doi: 10.1038/clpt.2011.126. Review. No abstract available. Erratum in: Clin Pharmacol Ther. 2011 Dec;90(6):893.

Items per page

Supplemental Content

Support Center